|
Components of
Meningococcal Vaccine
Indication
Active immunization against invasive meningococcal disease caused by Neisseria meningitidis serogroup A, C, Y, and W-135
Proprietary Name
Menveo Manufacturers
Novartis Viability
Inactivated
Inactivated
Inactivated
Approved Ages 9 mos - 55 years 2 years and older 2-55 years Microorganism
Neisseria meningitidis serogroup A, C, Y and W-135 capsular polysaccharide antigens
Group-specific polysaccharide antigens from Neisseria meningitidis, Group A, Group C, Group Y and Group W-135
Meningococcal (Groups A, C, Y and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine
Dose
0.5 mL
0.5 mL
0.5mL
Route
Intramuscular
Subcutaneous
Intramuscular
Dose form
Liquid
Freeze-dried preparation
Liquid
Appearance
Clear to slightly turbid liquid.
Clear, colorless liquid
Clear, colorless liquid
Concentration (per 0.5 mL)
Meningococcal A, C, Y, - 4 mcg each
W-135 polysaccharides, 4 mcg
Diphtheria toxoid protein carrier, 48 mcg
“Isolated product” from each of Groups A, C, Y and W-135 in an isotonic sodium chloride solution, 50 mcg each
MenA oligosaccharide, 10 mcg
MenC, MenY and MenW-135 oligosaccharides,5 mcg of each
CRM197 protein, 32.7 to 64.1 mcg
Preservatives
None
None in single dose vial
Thimerosal, 25 mcg multidose vial
None Adjuvants
None
None
None Excipients
Sodium phosphate buffered isotonic sodium chloride solution
Lactose, 2.5 to 5 mg
Formaldehyde, residual
CY medium containing yeast extracts and amino acids
Allergens
Stopper of the vial contains dry natural rubber latex
Stopper of the vial contains dry natural rubber latex
Media
Cultured on Mueller Hinton agar and grown in Watson Scherp media
Casamino acid medium and medium 199. N. Meningitidis are cultivated with Mueller Hinton agar1 and Watson Scherp2 media
Franz Complete medium and treated with formaldehyde
Packaging
Vial, single dose and 5 single-dose package
Vial, single dose + diluent
5 single dose + diluent packs
10-dose vial + dilent (not to be used with jet injector)
Vial of MenA lyophilized conjugate component and a vial of MenCYW-135 liquid conjugate component (1 dose after reconstitution). 5 doses (10 vials) per pack
Routine Storage
2 to 8° C (35-46° F)
Do not freeze
2 to 8° C (35-46° F)
Do not freeze
2 to 8° C (35-46° F)
Do not freeze
PI Last updated November 2011 May 2012 March 2011 updated September 2012
This page was last updated on November 07, 2012
© 2012 Institute for Vaccine Safety
